诺维本联合阿霉素一线治疗72例转移性乳腺癌

Vinorelbine (NVB) plus epirubicin (E-ADM) in first-line metastatic breast cancer chemotherapy

目的 分析 72例接受诺维本加表阿霉素联合化疗方案一线治疗转移性乳腺癌患者的疗效及毒性。方法 72例未经化疗的转移性乳腺癌患者 ,接受诺维本 2 5mg/m2 每周 ,静滴d1、d8,表阿霉素静注d1,每 3周重复。结果 72例可评价疗效、毒性、生存期 ,完全缓解 12 .5 % (9/ 72 ) ,部分缓解 6 5 .3% (4 7/ 72 ) ,稳定 18.1% (13/ 72 ) ,进展 4 .2 % (3/ 72 ) ,CR +PR 77.8% (5 6 /72 )。WHO血液血毒性 :在 36 0个化疗疗程中 ,Ⅲ和Ⅳ度粒细胞减少分别是 32 %和 16 % ,Ⅲ和Ⅳ度非血液血毒性低。中位病变进展时间 (TTP)为 13个月 (1～ 2 3月 ) ,中位生存期为 2 5个月 (3～ 34月 )。结论 诺维本联合表阿霉素一线治疗转移性乳腺癌疗效高、毒性低。

Objective From January 1997 to December 2002, 72 cases of metastatic breast cancer were treated by NVB plus E-ADM as first line therapy to evatuate the response rates, toxicities,median time to progression (TTP),median survival duration(MS). Methods NVB was administered at a dose of 25mg/m 2 at day 1 and day 8 combined with E-ADM 60mg/m 2 at day 1 and day 21(21 days is a cycle in this paper) cycle. Results 72 patients were available to evaluate the outcomes where complete restoration complete restoration was 12.5% (9/72), partial restoration was 65.3%(47/72). Stable disease (SD) and disease progression (PD) was 18.1%(13/72) and 4.2%(3/72), respectively, TTP was 13 months (1-23months), MS was 25 months (3-34 months). WHO Grade 3/4 neutropenia occurred in 32% and 16% of 360 cycles, respectively. None of patients died from hematological toxicity. Non-hematological toxicity was mild. Condusion NVB/E-ADM combination for patients with adanced breast cancer showed high activity and low toxicity.